Contraception News and Research

Latest Contraception News and Research

Research: Myths about migration and health not supported by available evidence

Research published in The Lancet on 5 December revealed that harmful and unfounded myths about migration and health have become accepted and that these are used to justify policies of exclusion.

13 Dec 2018

New book encompasses the vast history of reproduction

A new book is the first to encompass the vast history of how living things procreate, from the banks of the ancient Nile to the fertility clinics of today.

7 Dec 2018

Low-income women in Texas are not receiving contraception after childbirth, study shows

Low-income women in Texas who have delivered a baby are not getting the contraception they want at their six-week postpartum visit, a new study from the Texas Policy Evaluation Project shows.

5 Dec 2018

Abused women more likely to seek emergency contraception, study finds

Women who experience domestic violence and abuse are more than twice as likely to seek emergency contraception as other women, according to a study by National Institute for Health Research-funded researchers at the University of Bristol and Queen Mary University of London, suggesting that requests for emergency contraception could be an important sign of abuse.

4 Dec 2018

Women’s intentions and attitude matter when it comes to using contraception

A new Veterans Affairs study adds to the evidence that women's intentions around becoming pregnant don't fully explain whether and how they use contraception. Rather, their attitudes toward becoming pregnant also play a role.

30 Nov 2018

Gel formulation of a new male contraceptive on trial

The National Institutes of Health (NIH) is funding a clinical trial to see the safety and effectiveness of a new male contraceptive that would be available in gel formulation.

29 Nov 2018

FDA approves new treatment for AML patients

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

22 Nov 2018

Nexus announces availability of Arsenic Trioxide Injection in the US

Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.

16 Nov 2018

Both parents and children agree about confidential medical services

When it comes to preventive care and confidential medical services, parents and their adolescent children actually agree with each other. They both believe that preventive care is important, that adolescents should be provided with opportunities to speak with their doctor one-on-one, and that some services should be confidential.

15 Nov 2018

Infant girls fed soy formula more likely to develop severe menstrual pain as adults, suggests research

New research suggests that infant girls fed soy formula are more likely to develop severe menstrual pain as young adults. The finding adds to the growing body of literature that suggests exposure to soy formula during early life may have detrimental effects on the reproductive system. The study appears online in the journal Human Reproduction.

9 Nov 2018

Vulnerable young teenagers urgently need better sex education, say researchers

Sexually active teenagers who were offered rapid, confidential chlamydia testing and same-day treatment at college mostly did not take up the offer, largely due to ignorance about the risks.

9 Nov 2018

UTSA research could help address genetically based challenges with male fertility

Millions of couples who have trouble conceiving may get relief from new research led by scientists at The University of Texas at San Antonio.

7 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Study finds increased risks to mother and baby when pregnancies are closely spaced

Twelve to 18 months seems to be the ideal length of time between giving birth and getting pregnant again, according to new research from the University of British Columbia and the Harvard T.H. Chan School of Public Health.

29 Oct 2018

Novel test measures male fertility

At a time when more than half of male infertility cannot be explained by current methods, a new test developed by Androvia LifeSciences is able to measure male fertility.

25 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Contraception News and Research

Latest Contraception News and Research

Research: Myths about migration and health not supported by available evidence

New book encompasses the vast history of reproduction

Low-income women in Texas are not receiving contraception after childbirth, study shows

Abused women more likely to seek emergency contraception, study finds

Women’s intentions and attitude matter when it comes to using contraception

Gel formulation of a new male contraceptive on trial

FDA approves new treatment for AML patients

Nexus announces availability of Arsenic Trioxide Injection in the US

Both parents and children agree about confidential medical services

Infant girls fed soy formula more likely to develop severe menstrual pain as adults, suggests research

Vulnerable young teenagers urgently need better sex education, say researchers

UTSA research could help address genetically based challenges with male fertility

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Study finds increased risks to mother and baby when pregnancies are closely spaced

Novel test measures male fertility

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Contraception News and Research

Latest Contraception News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in